Angiogenesis
The growth of blood vessels (a process known as angiogenesis) is essential for organ growth and repair. Blood vessels arose during evolution to carry oxygen to distant organs. Not surprisingly, these vessels are crucial for organ growth in the embryo and repair of wounded tissue in the adult. An imbalance in this process contributes to numerous malignant, inflammatory, ischaemic, infectious and immune disorders.
In the embryo, blood vessels provide the growing organs with the necessary oxygen to develop. Apart from their nutritive function, vessels also provide instructive trophic signals to promote organ morphogenesis. Blood vessels arise from endothelial precursors, which share an origin with haematopoietic progenitors. The close link between the blood and blood vascular systems remains important for angiogenesis throughout life, even in disease. These progenitors assemble into a primitive vascular labyrinth of small capillaries — a process known as vasculogenesis.
Over the past 15 years, genetic studies in mice, zebrafish and tadpoles have provided insights into the key mechanisms and molecular players that regulate the growth of blood vessels (angiogenesis) or lymph vessels (lymphangiogenesis) in the embryo. Implications of members of the Notch family, the orphan receptor COUP-TFII, the homeobox geneProx-1, angiopoietin, PDGF, VEGF and its homologue VEGF-C have been confirmed, among others.
The formation of vessels is a complex process, requiring a finely tuned balance between numerous stimulatory and inhibitory signals, such as integrins, angiopoietins, chemokines, junctional molecules, oxygen sensors, endogenous inhibitors and many others[1].
[1] P. Carmeliet. Angiogenesis in life, disease and medicine. Nature 2005, 438, 932-936.
Axon ID | Name | Description | From price | |
---|---|---|---|---|
2496 | 2,5-Dimethylcelecoxib | Celecoxib analog with anti-tumor properties, lacking COX-2 inhibitory activity | €75.00 | |
1666 | A 357300 hydrochloride | MetAP2 inhibitor | €90.00 | |
1419 | AB 1010 | PDGFR, c-KIT and FGFR3 tyrosine kinase inhibitor | €70.00 | |
3631 | ABR-238901 | Potent S100A8/A9 blocker | €170.00 | |
1638 | ABT 869 | PDGFR, c-KIT and VEGFR tyrosine kinase inhibitor | €85.00 | |
1653 | AEE 788 | EGFR, ErbB2 and VEGFR tyrosine kinase inhibitor | €80.00 | |
1414 | AG 013736 | PDGFR,c-KIT and VEGFR tyrosine kinase inhibitor | €50.00 | |
2930 | Alofanib | Allosteric inhibitor of FGFR2 | €90.00 | |
1768 | AMG 706 | Multiple receptor tyrosine kinase inhibitor | €105.00 | |
2368 | Amuvatinib | RTK inhibitor which effectively inhibits PDGFR, c-Kit and c-Met | €105.00 | |
2849 | Apatinib | Inhibitor of VEGFR2 | €120.00 | |
1369 | Apilimod | Cytokine inhibitor; IL-12 and IL-23 inhibitor | €110.00 | |
2500 | Apilimod dimesylate | Cytokine inhibitor; IL-12 and IL-23 inhibitor | €110.00 | |
2191 | AR 244555 | Inverse agonist of Mas G-protein signaling | €125.00 | |
1986 | AST 1306 tosylate | ErbB2 and EGFR inhibitor | €90.00 | |
5051 | Axon Ligands™ Cell signaling and Oncology compound library | Axon Ligands™ Cell signaling and Oncology compound library | Inquire | |
2661 | AZD2716 | Potent secreted phospholipase A2 (sPLA2) inhibitor | €145.00 | |
2563 | AZD3759 | Potent, orally active, brain-penetrant, EGFR tyrosine kinase inhibitor | €85.00 | |
1917 | AZD4547 | Potent and selective FGFR inhibitor | €85.00 | |
2342 | AZD9291 | Potent oral, irreversible, third-generation EGFR TKI with selectivity for mutant EGFRs | €95.00 | |
2178 | BCI | Allosteric inhibitor of dual-specificity phosphatases (DUSP) | €75.00 | |
2852 | BCI hydrochloride | Allosteric inhibitor of dual-specificity phosphatases (DUSP) | €75.00 | |
1544 | BIBW 2992 | EGFR and ErbB-2/HER2 tyrosine kinase inhibitor | €50.00 | |
1850 | BMS 540215 | Inhibitor of VEGFR (subtype 2 and 3 selective) | €110.00 | |
2837 | BMS 605541 | Potent, selective, orally active, and ATP-competitive VEGFR2 inhibitor | €90.00 | |
1864 | Brivanib alaninate | Prodrug of BMS 540215; Inhibitor of VEGF | €90.00 | |
3481 | BTYNB isomer | Ring-closed isomer of BTYNB | €110.00 | |
1819 | Cabozantinib S-malate | Inhibitor of multiple receptor tyrosine kinases, specifically MET and VEGFR2 | €60.00 | |
1461 | Cediranib | VEGFR tyrosine kinase inhibitor | €70.00 | |
2250 | CHR 6494 trifluoroacetate | Specific, first-in-class inhibitor of histone kinase Haspin | €120.00 |